Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3020808 | 0.79 | LTB4R (0.33) | ALDH1A1HPGD | |
| SCHEMBL4092936 | 0.76 | — | — | |
| SCHEMBL2243607 | 0.76 | — | — | |
| SCHEMBL13902223 | 0.76 | — | — | |
| SCHEMBL4769454 | 0.76 | POLB (0.34) | ALDH1A1HPGD | |
| SCHEMBL2975970 | 0.76 | — | — | |
| SCHEMBL8747072 | 0.76 | — | — | |
| SCHEMBL2986012 | 0.76 | — | — | |
| SCHEMBL11710162 | 0.74 | NPSR1 (0.39) | ALDH1A1 | |
| SCHEMBL20562095 | 0.71 | KEAP1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469741-B2 | Polymers functionalized with heterocyclic nitrile compounds | BRIDGESTONE CORPORATION (JP) | 2016-10-18 | — | — | US | claimed |
| EP-2203482-B1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORP (JP) | 2015-11-25 | — | — | EP | claimed |
| US-20150267031-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2015-09-24 | — | — | US | claimed |
| US-9085646-B2 | Polymers functionalized with heterocyclic nitrile compounds | BRIDGESTONE CORPORATION (JP) | 2015-07-21 | — | — | US | claimed |
| US-20130066016-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2013-03-14 | — | — | US | claimed |
| US-8362156-B2 | Polymers functionalized with heterocyclic nitrile compounds | BRIDGESTONE CORPORATION (JP) | 2013-01-29 | — | — | US | claimed |
| US-8314189-B2 | Polymers functionalized with heterocyclic nitrile compounds | BRIDGESTONE CORPORATION (JP) | 2012-11-20 | — | — | US | claimed |
| US-20100280217-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2010-11-04 | — | — | US | claimed |
| EP-2203482-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | Bridgestone Corporation (JP) | 2010-07-07 | — | — | EP | claimed |
| WO-2009051702-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2009-04-23 | — | — | WO | claimed |
| WO-2009051700-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION (US) | 2009-04-23 | — | — | WO | claimed |
| US-20090099325-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION | 2009-04-16 | — | — | US | claimed |
| WO-2026102105-A1 | FUNCTIONAL POLYBUTADIENE AND CARBON BLACK IN RUBBER COMPOUNDS | BRIDGESTONE AMERICAS TIRE OPERATIONS, LLC (US) | 2026-05-15 | — | — | WO | disclosed |
| US-11512148-B2 | Composition including multiple terminally functionalized polymers | BRIDGESTONE CORPORATION (JP) | 2022-11-29 | — | — | US | disclosed |
| US-20220153885-A1 | PROCESS FOR PRODUCING FUNCTIONALIZED POLYMERS | BRIDGESTONE CORPORATION (JP) | 2022-05-19 | — | — | US | disclosed |
| EP-3458488-B1 | PROCESS FOR PRODUCING FUNCTIONALIZED POLYMERS | BRIDGESTONE CORP (JP) | 2020-12-30 | — | — | EP | disclosed |
| US-7361671-B2 | Substituted heteroarylalkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1444228-A2 | SUBSTITUTED HETEROARYLALKANOIC ACIDS AND THEIR USE AS ALDOSE REDUCTASE INHIBITORS | The Institutes for Pharmaceutical Discovery, LLC (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20030166668-A1 | Substituted heteroarylalkanoic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, INC. A CORPORATION OF THE STATE OF DELAWARE | 2003-09-04 | — | — | US | disclosed |
| WO-2003044015-A2 | SUBSTITUTED HETEROARYLALKANOIC ACIDS AND THEIR USE AS ALDOSE REDUCTASE INHIBITORS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166668-A1 | Substituted heteroarylalkanoic acids | GPR119, LIPA, DDC | CYP2A6 42/4885ALDH1A1 270/4885HPGD 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.